• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Alector Inc.

    11/13/25 4:41:55 PM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ALEC alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 6)


    Alector, Inc.

    (Name of Issuer)


    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)


    014442107

    (CUSIP Number)


    09/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    014442107


    1Names of Reporting Persons

    Polaris Venture Partners VI, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    498,468.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    498,468.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    498,468.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.5 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:   All shares are held of record by PVP VI (as defined in Item 2(a) of the Original Schedule 13G (as defined below)). PVM VI (as defined in Item 2(a) of the Original Schedule 13G), the general partner of PVP VI, may be deemed to have voting, investment and dispositive power with respect to these securities. David Barrett, Brian Chee, Jonathan A. Flint, Terrance G. McGuire, Amir Nashat, and Bryce Youngren are the managing members of PVM VI and may each be deemed to share voting, investment and dispositive power with respect to these securities. The percentage in Row 11 is based on 109,151,472 shares of the Issuer's common stock ("Common Stock") outstanding as of October 31, 2025, as set forth in the Issuer's quarterly report on Form 10-Q for the quarter ended September 30, 2025, filed with the United States Securities and Exchange Commission (the "Commission") on November 6, 2025 (the "Form 10-Q").


    SCHEDULE 13G

    CUSIP No.
    014442107


    1Names of Reporting Persons

    Polaris Venture Partners Founders' Fund VI, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    378,403.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    378,403.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    378,403.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.3 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:   All shares are held of record by PVPFF VI (as defined in Item 2(a) of the Original Schedule 13G). PVM VI, the general partner of PVPFF VI, may be deemed to have voting, investment and dispositive power with respect to these securities. David Barrett, Brian Chee, Jonathan A. Flint, Terrance G. McGuire, Amir Nashat, and Bryce Youngren are the managing members of PVM VI and may each be deemed to share voting, investment and dispositive power with respect to these securities. The percentage in Row 11 is based on 109,151,472 shares of Common Stock outstanding as of October 31, 2025, as set forth in the Form 10-Q.


    SCHEDULE 13G

    CUSIP No.
    014442107


    1Names of Reporting Persons

    Polaris Venture Partners VI (AIV), L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    4,797,563.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    4,797,563.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,797,563.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.4 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:   All shares are held of record by PVP VI (AIV) (as defined in Item 2(a) of the Original Schedule 13G). PVM VI, the general partner of PVP VI (AIV), may be deemed to have voting, investment and dispositive power with respect to these securities. David Barrett, Brian Chee, Jonathan A. Flint, Terrance G. McGuire, Amir Nashat, and Bryce Youngren are the managing members of PVM VI and may each be deemed to share voting, investment and dispositive power with respect to these securities. The percentage in Row 11 is based on 109,151,472 shares of Common Stock outstanding as of October 31, 2025, as set forth in the Form 10-Q.


    SCHEDULE 13G

    CUSIP No.
    014442107


    1Names of Reporting Persons

    Polaris Venture Partners VI (AIV-B), L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    1,179,383.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    1,179,383.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,179,383.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    1.1 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:   All shares are held of record by PVP VI (AIV-B) (as defined in Item 2(a) of the Original Schedule 13G). PVM VI, the general partner of PVP VI (AIV-B), may be deemed to have voting, investment and dispositive power with respect to these securities. David Barrett, Brian Chee, Jonathan A. Flint, Terrance G. McGuire, Amir Nashat, and Bryce Youngren are the managing members of PVM VI and may each be deemed to share voting, investment and dispositive power with respect to these securities. Based on 109,151,472 shares of Common Stock outstanding as of October 31, 2025, as set forth in the Form 10-Q.


    SCHEDULE 13G

    CUSIP No.
    014442107


    1Names of Reporting Persons

    Polaris Venture Management Co VI, L.L.C.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    6,853,817.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    6,853,817.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,853,817.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.3 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:   The shares reported in Rows 6 and 8 consist of (i) 498,468 shares held of record by PVP VI, (ii) 378,403 shares held of record by PVPFF VI, (iii) 4,797,563 shares held of record by PVP VI (AIV) and (iv) 1,179,383 shares held of record by PVP VI (AIV-B). PVM VI, the general partner of each of PVP VI, PVPFF VI, PVP VI (AIV) and PVP VI (AIV-B), may be deemed to have voting, investment and dispositive power with respect to these securities. David Barrett, Brian Chee, Jonathan A. Flint, Terrance G. McGuire, Amir Nashat, and Bryce Youngren are the managing members of PVM VI and may each be deemed to share voting, investment and dispositive power with respect to these securities. The percentage in Row 11 is based on 109,151,472 shares of Common Stock outstanding as of October 31, 2025, as set forth in the Form 10-Q.


    SCHEDULE 13G

    CUSIP No.
    014442107


    1Names of Reporting Persons

    David Barrett
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    26,254.00
    6Shared Voting Power

    6,853,817.00
    7Sole Dispositive Power

    26,254.00
    8Shared Dispositive Power

    6,853,817.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,880,071.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.3 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:   The shares reported in Rows 5 and 7 are held directly by David Barrett. The shares reported in Rows 6 and 8 consist of (i) 498,468 shares held of record by PVP VI, (ii) 378,403 shares held of record by PVPFF VI, (iii) 4,797,563 shares held of record by PVP VI (AIV) and (iv) 1,179,383 shares held of record by PVP VI (AIV-B). PVM VI, the general partner of each of PVP VI, PVPFF VI, PVP VI (AIV) and PVP VI (AIV-B), may be deemed to have voting, investment and dispositive power with respect to these securities. David Barrett, Brian Chee, Jonathan A. Flint, Terrance G. McGuire, Amir Nashat, and Bryce Youngren are the managing members of PVM VI and may each be deemed to share voting, investment and dispositive power with respect to these securities. The percentage in Row 11 is based on 109,151,472 shares of Common Stock outstanding as of October 31, 2025, as set forth in the Form 10-Q.


    SCHEDULE 13G

    CUSIP No.
    014442107


    1Names of Reporting Persons

    Brian Chee
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    26,267.00
    6Shared Voting Power

    6,853,817.00
    7Sole Dispositive Power

    26,267.00
    8Shared Dispositive Power

    6,853,817.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,880,084.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.3 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:   The shares reported in Rows 5 and 7 are held directly by Brian Chee. The shares reported in Rows 6 and 8 consist of (i) 498,468 shares held of record by PVP VI, (ii) 378,403 shares held of record by PVPFF VI (iii) 4,797,563 shares held of record by PVP VI (AIV) and (iv) 1,179,383 shares held of record by PVP VI (AIV-B). PVM VI, the general partner of each of PVP VI, PVPFF VI, PVP VI (AIV) and PVP VI (AIV-B), may be deemed to have voting, investment and dispositive power with respect to these securities. David Barrett, Brian Chee, Jonathan A. Flint, Terrance G. McGuire, Amir Nashat, and Bryce Youngren are the managing members of PVM VI and may each be deemed to share voting, investment and dispositive power with respect to these securities. The percentage in Row 11 is based on 109,151,472 shares of Common Stock outstanding as of October 31, 2025, as set forth in the Form 10-Q.


    SCHEDULE 13G

    CUSIP No.
    014442107


    1Names of Reporting Persons

    Jonathan A. Flint
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    39,125.00
    6Shared Voting Power

    6,853,817.00
    7Sole Dispositive Power

    39,125.00
    8Shared Dispositive Power

    6,853,817.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,892,942.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.3 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:   The shares reported in Rows 5 and 7 are held directly by Jonathan A. Flint. The shares reported in Rows 6 and 8 consist of (i) 498,468 shares held of record by PVP VI, (ii) 378,403 shares held of record by PVPFF VI (iii) 4,797,563 shares held of record by PVP VI (AIV) and (iv) 1,179,383 shares held of record by PVP VI (AIV-B). PVM VI, the general partner of each of PVP VI, PVPFF VI, PVP VI (AIV) and PVP VI (AIV-B), may be deemed to have voting, investment and dispositive power with respect to these securities. David Barrett, Brian Chee, Jonathan A. Flint, Terrance G. McGuire, Amir Nashat, and Bryce Youngren are the managing members of PVM VI and may each be deemed to share voting, investment and dispositive power with respect to these securities. The percentage in Row 11 is based on 109,151,472 shares of Common Stock outstanding as of October 31, 2025, as set forth in the Form 10-Q.


    SCHEDULE 13G

    CUSIP No.
    014442107


    1Names of Reporting Persons

    Terrance G. McGuire
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    241,434.00
    6Shared Voting Power

    6,853,817.00
    7Sole Dispositive Power

    241,434.00
    8Shared Dispositive Power

    6,853,817.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    7,095,251.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.5 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:   The shares reported in Rows 5 and 7 consist of (i) 70,719 shares held directly by Terrance G. McGuire, (ii) 144,465 shares held by McGuire Family Trust, and (iii) 26,250 shares consist of restricted stock units that have been granted to Terrance G. McGuire in his capacity as a former director of the Issuer. Terrance G. McGuire is the donor of the McGuire Family Trust and may be deemed to share voting, investment and dispositive power with respect to the shares held by the McGuire Family Trust. The shares reported in Rows 6 and 8 consist of (i) 498,468 shares held of record by PVP VI, (ii) 378,403 shares held of record by PVPFF VI (iii) 4,797,563 shares held of record by PVP VI (AIV) and (iv) 1,179,383 shares held of record by PVP VI (AIV-B). PVM VI, the general partner of each of PVP VI, PVPFF VI, PVP VI (AIV) and PVP VI (AIV-B), may be deemed to have voting, investment and dispositive power with respect to these securities. David Barrett, Brian Chee, Jonathan A. Flint, Terrance G. McGuire, Amir Nashat, and Bryce Youngren are the managing members of PVM VI and may each be deemed to share voting, investment and dispositive power with respect to these securities. The percentage in Row 11 is based on 109,177,722 shares of Common Stock, calculated as follows: (i) 26,250 shares that represent restricted stock units that have been granted to Mr. McGuire in his capacity as a former director of the Issuer plus (ii) 109,151,472 shares of Common Stock outstanding as of October 31, 2025, as set forth in the Form 10-Q.


    SCHEDULE 13G

    CUSIP No.
    014442107


    1Names of Reporting Persons

    Amir Nashat
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    78,800.00
    6Shared Voting Power

    6,853,817.00
    7Sole Dispositive Power

    78,800.00
    8Shared Dispositive Power

    6,853,817.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,932,617.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.4 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:   The shares reported in Rows 5 and 7 are held directly by Amir Nashat. The shares reported in Rows 6 and 8 consist of (i) 498,468 shares held of record by PVP VI, (ii) 378,403 shares held of record by PVPFF VI, (iii) 4,797,563 shares held of record by PVP VI (AIV) and (iv) 1,179,383 shares held of record by PVP VI (AIV-B). PVM VI, the general partner of each of PVP VI, PVPFF VI, PVP VI (AIV) and PVP VI (AIV-B), may be deemed to have voting, investment and dispositive power with respect to these securities. David Barrett, Brian Chee, Jonathan A. Flint, Terrance G. McGuire, Amir Nashat, and Bryce Youngren are the managing members of PVM VI and may each be deemed to share voting, investment and dispositive power with respect to these securities. The percentage in Row 11 is based on 109,151,472 shares of Common Stock outstanding as of October 31, 2025, as set forth in the Form 10-Q.


    SCHEDULE 13G

    CUSIP No.
    014442107


    1Names of Reporting Persons

    Bryce Youngren
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    91,332.00
    6Shared Voting Power

    6,853,817.00
    7Sole Dispositive Power

    91,332.00
    8Shared Dispositive Power

    6,853,817.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,945,149.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.4 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:   The shares reported in Rows 5 and 7 are held directly by Bryce Youngren. The shares reported in Rows 6 and 8 consist of (i) 498,468 shares held of record by PVP VI, (ii) 378,403 shares held of record by PVPFF VI (iii) 4,797,563 shares held of record by PVP VI (AIV) and (iv) 1,179,383 shares held of record by PVP VI (AIV-B). PVM VI, the general partner of each of PVP VI, PVPFF VI, PVP VI (AIV) and PVP VI (AIV-B), may be deemed to have voting, investment and dispositive power with respect to these securities. David Barrett, Brian Chee, Jonathan A. Flint, Terrance G. McGuire, Amir Nashat, and Bryce Youngren are the managing members of PVM VI and may each be deemed to share voting, investment and dispositive power with respect to these securities. The percentage in Row 11 is based on 109,151,472 shares of Common Stock outstanding as of October 31, 2025, as set forth in the Form 10-Q.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Alector, Inc.
    (b)Address of issuer's principal executive offices:

    131 OYSTER POINT BLVD., SUITE 600, SOUTH SAN FRANCISCO, CA, 94080
    Item 2. 
    (a)Name of person filing:

    This Amendment No. 6 (this "Amendment") amends and supplements the Schedule 13G initially filed with the Commission on February 12, 2020, as amended by Amendment No. 1 filed with the Commission on February 12, 2021, Amendment No. 2 filed with the Commission on February 11, 2022, Amendment No. 3 filed with the Commission on February 7, 2023, Amendment No. 4 filed with the Commission on February 9, 2024 and Amendment No. 5 filed with the Commission on November 12, 2024 (collectively, the "Original Schedule 13G"). Only those items that are hereby reported are amended; all other items reported in the Original Schedule 13G remain unchanged. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable. Capitalized terms not defined in this Amendment have the meanings ascribed to them in the Original Schedule 13G. The following information in Item 4 with respect to the ownership of the Issuer's Common Stock by the Reporting Persons filing this Amendment No. 6 is provided as of November 6, 2025. Each of the Reporting Persons disclaims beneficial ownership of the shares of Common Stock reported in this Amendment No. 6, except for the shares, if any, such Reporting Person holds of record and to the extent of such Reporting Person's pecuniary interest therein.
    (b)Address or principal business office or, if none, residence:

    (c)Citizenship:

    (d)Title of class of securities:

    Common Stock, $0.0001 par value per share
    (e)CUSIP No.:

    014442107
    Item 4.Ownership
    (a)Amount beneficially owned:

    See Row 9 of cover page for each Reporting Person and the corresponding footnotes.
    (b)Percent of class:

    See Row 11 of cover page for each Reporting Person and the corresponding footnotes.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See Row 5 of cover page for each Reporting Person and the corresponding footnotes.

     (ii) Shared power to vote or to direct the vote:

    See Row 6 of cover page for each Reporting Person and the corresponding footnotes.

     (iii) Sole power to dispose or to direct the disposition of:

    See Row 7 of cover page for each Reporting Person and the corresponding footnotes.

     (iv) Shared power to dispose or to direct the disposition of:

    See Row 8 of cover page for each Reporting Person and the corresponding footnotes.


    Item 10.Certifications:
     

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Polaris Venture Partners VI, L.P.
     
    Signature:/s/ Lauren Crockett
    Name/Title:Lauren Crockett/ Authorized Signatory of Polaris Venture Management Co. VI, L.L.C., general partner of Polaris Venture Partners VI, L.P.
    Date:11/13/2025
     
    Polaris Venture Partners Founders' Fund VI, L.P.
     
    Signature:/s/ Lauren Crockett
    Name/Title:Lauren Crockett/ Authorized Signatory of Polaris Venture Management Co. VI, L.L.C., GP of Polaris Venture Partners Founders' Fund VI, L.P.
    Date:11/13/2025
     
    Polaris Venture Partners VI (AIV), L.P.
     
    Signature:/s/ Lauren Crockett
    Name/Title:Lauren Crockett/ Authorized Signatory of Polaris Venture Management Co. VI, L.L.C., general partner of Polaris Venture Partners VI (AIV), L.P.
    Date:11/13/2025
     
    Polaris Venture Partners VI (AIV-B), L.P.
     
    Signature:/s/ Lauren Crockett
    Name/Title:Lauren Crockett/ Authorized Signatory of Polaris Venture Management Co. VI, L.L.C., general partner of Polaris Venture Partners VI (AIV-B), L.P.
    Date:11/13/2025
     
    Polaris Venture Management Co VI, L.L.C.
     
    Signature:/s/ Lauren Crockett
    Name/Title:Lauren Crockett/ Authorized Signatory*
    Date:11/13/2025
     
    David Barrett
     
    Signature:/s/ Lauren Crockett
    Name/Title:Lauren Crockett/ Attorney-In-Fact
    Date:11/13/2025
     
    Brian Chee
     
    Signature:/s/ Lauren Crockett
    Name/Title:Lauren Crockett/ Attorney-In-Fact
    Date:11/13/2025
     
    Jonathan A. Flint
     
    Signature:/s/ Lauren Crockett
    Name/Title:Lauren Crockett/ Attorney-In-Fact
    Date:11/13/2025
     
    Terrance G. McGuire
     
    Signature:/s/ Lauren Crockett
    Name/Title:Lauren Crockett/ Attorney-In-Fact
    Date:11/13/2025
     
    Amir Nashat
     
    Signature:/s/ Lauren Crockett
    Name/Title:Lauren Crockett/ Attorney-In-Fact
    Date:11/13/2025
     
    Bryce Youngren
     
    Signature:/s/ Lauren Crockett
    Name/Title:Lauren Crockett/ Attorney-In-Fact
    Date:11/13/2025

    Comments accompanying signature:  This Schedule 13G was executed pursuant to a Power of Attorney. Note that copies of the applicable Power of Attorney are already on file with the appropriate agencies.
    Get the next $ALEC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALEC

    DatePrice TargetRatingAnalyst
    10/22/2025$1.50Outperform → Neutral
    Mizuho
    10/22/2025Buy → Hold
    TD Cowen
    10/22/2025Overweight → Neutral
    Cantor Fitzgerald
    10/22/2025Outperform → Mkt Perform
    William Blair
    10/22/2025Buy → Neutral
    BTIG Research
    7/28/2025$3.50Neutral → Outperform
    Mizuho
    12/17/2024$9.00 → $2.50Outperform → Neutral
    Mizuho
    12/16/2024$4.00Buy → Hold
    Stifel
    More analyst ratings

    $ALEC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alector downgraded by Mizuho with a new price target

    Mizuho downgraded Alector from Outperform to Neutral and set a new price target of $1.50

    10/22/25 7:10:52 AM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Alector downgraded by TD Cowen

    TD Cowen downgraded Alector from Buy to Hold

    10/22/25 7:10:36 AM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Alector downgraded by Cantor Fitzgerald

    Cantor Fitzgerald downgraded Alector from Overweight to Neutral

    10/22/25 7:10:36 AM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALEC
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Alector Inc.

    SCHEDULE 13G - Alector, Inc. (0001653087) (Subject)

    11/14/25 8:18:22 AM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Alector Inc.

    SCHEDULE 13G/A - Alector, Inc. (0001653087) (Subject)

    11/13/25 4:41:55 PM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Alector Inc.

    SCHEDULE 13G/A - Alector, Inc. (0001653087) (Subject)

    11/7/25 11:13:45 AM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALEC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Principal Accounting Officer Wong-Sarad Grace was granted 32,343 shares, increasing direct ownership by 31% to 135,791 units (SEC Form 4)

    4 - Alector, Inc. (0001653087) (Issuer)

    11/12/25 4:19:25 PM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Bus Ofcr & Interim CFO Berkley Neil Lindsay was granted 65,000 shares, increasing direct ownership by 19% to 411,570 units (SEC Form 4)

    4 - Alector, Inc. (0001653087) (Issuer)

    11/12/25 4:17:18 PM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Rosenthal Arnon was granted 174,167 shares, increasing direct ownership by 7% to 2,524,387 units (SEC Form 4)

    4 - Alector, Inc. (0001653087) (Issuer)

    11/12/25 4:10:27 PM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALEC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Alector Reports Third Quarter 2025 Financial Results and Provides Business Update

    Selected lead candidates AL137 for the company's Alector Brain Carrier (ABC)-enabled anti-amyloid beta antibody in Alzheimer's disease, and AL050 for its ABC-enabled GCase enzyme replacement therapy in Parkinson's disease; both advancing toward IND-enabling studies Advancing ABC-enabled Tau, Alpha Synuclein and NLRP3 siRNA programs targeting peripheral delivery of novel therapies for neurodegenerative disorders Independent interim analysis for the PROGRESS-AD Phase 2 clinical trial of nivisnebart (AL101) in early Alzheimer's disease planned for 1H 2026 $291.1 million in cash, cash equivalents, and investments provides runway through 2027 SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOB

    11/6/25 4:05:00 PM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Alector Announces Topline Results from Latozinemab Phase 3 Trial in Individuals with Frontotemporal Dementia Due to a GRN Mutation and Provides Business Update

    SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced results from the Phase 3 INFRONT-3 clinical trial evaluating latozinemab (AL001) in individuals with frontotemporal dementia due to a progranulin gene mutation (FTD-GRN). In the 96-week, double-blind INFRONT-3 trial, latozinemab, developed in collaboration with GSK, did not meet the clinical co-primary endpoint of slowing FTD-GRN progression, as measured by the Clinical Dementia Rating® plus National Alzheimer's Coordinating Center Frontotemporal Lob

    10/21/25 4:05:00 PM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Alector to Host Virtual Research and Development Event Highlighting PGRN Franchise and Brain Carrier Programs

    SOUTH SAN FRANCISCO, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced management will host a virtual event to discuss the company's progranulin (PGRN) franchise and Alector Brain Carrier (ABC)–enabled programs. The event will include a review of latozinemab, currently being evaluated in a pivotal Phase 3 trial for frontotemporal dementia due to a GRN gene mutation, and AL101, which is in a Phase 2 trial for early Alzheimer's disease (AD). In addition, the company will present preclinical data on lead candidates fo

    9/16/25 8:00:00 AM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALEC
    Financials

    Live finance-specific insights

    View All

    Alector Reports Second Quarter 2025 Financial Results and Provides Business Update

    On track to report topline data by mid-Q4 2025 from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN, a severe, rare form of dementia with no approved treatments Ongoing Phase 2 PROGRESS-AD trial of AL101 in early Alzheimer's disease expected to complete in 2026 Continuing to progress Alector Brain Carrier programs, including the company's anti-amyloid beta antibody, engineered GCase enzyme replacement therapy, and anti-tau siRNA $307.3 million in cash, cash equivalents, and investments provides runway into the second half of 2027 Management to host conference call and webcast today at 4:30 p.m. ET/1:30 p.m. PT SOUTH SAN FRANCISCO, Calif., Aug. 07, 2025 (GLOBE NE

    8/7/25 4:05:00 PM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Alector to Host Second Quarter and Mid-Year 2025 Earnings Conference Call

    SOUTH SAN FRANCISCO, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced it will host a conference call and webcast on Thursday, August 7, 2025, at 4:30 p.m. ET to discuss results for the second quarter ended June 30, 2025, and provide a mid-year business update. The call will feature remarks from Ryan Darby, M.D., Associate Professor of Neurology and Director of the Frontotemporal Dementia Clinic at Vanderbilt University Medical Center, who will speak on the unmet need in frontotemporal dementia. A press release deta

    7/31/25 4:05:00 PM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Alector Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

    Topline data from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN expected by Q4 2025 Anticipate completing enrollment in the PROGRESS-AD Phase 2 clinical trial of AL101/GSK4527226 in participants with early Alzheimer's disease by mid-2025 Applying Alector Brain Carrier to advance therapeutic candidates, including those targeting amyloid beta and replacing GCase $413.4 million in cash, cash equivalents and investments provide runway through 2026 Management to host conference call and webcast today at 4:30 p.m. ET/1:30 p.m. PT SOUTH SAN FRANCISCO, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a late-stage clinical biotechnology company

    2/26/25 4:05:00 PM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALEC
    Leadership Updates

    Live Leadership Updates

    View All

    Alector Reports First Quarter 2024 Financial Results and Provides Business Update

    Data from INVOKE-2, evaluating the most advanced TREM2 candidate in clinical development for early Alzheimer's disease, on track for Q4 2024 Strengthened leadership team with key appointments: Neil Berkley, M.S., M.B.A., named Chief Business Officer; Errol De Souza, Ph.D., and Mark Altmeyer, M.B.A., join Board of Directors $562.1 million in cash, cash equivalents and investments provide runway through 2026 SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today reported first quarter 2024 financial results and recent portfolio and business updates. As of March 31, 202

    5/8/24 4:05:00 PM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Alector Announces Appointment of Gary Romano, M.D., Ph.D., as Chief Medical Officer

    SOUTH SAN FRANCISCO, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the appointment of Gary Romano, M.D., Ph.D., as Chief Medical Officer. In this role, Dr. Romano will lead the company's global clinical development strategy, including oversight of the clinical development, clinical operations, biometrics and digital science, and medical affairs functions. Dr. Romano will report to Sara Kenkare-Mitra, Ph.D., President and Head of Research and Development of Alector. Dr. Romano's appointment is effective May 23, 2022. "We are delighted to welcome Gary to our executive leadership tea

    3/29/22 4:05:00 PM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Alector Announces Appointment of Marc Grasso, M.D., as Chief Financial Officer

    SOUTH SAN FRANCISCO, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering the discovery and development of immuno-neurology therapeutics, today announced the appointment of Marc Grasso, M.D., as Chief Financial Officer (CFO). Dr. Grasso brings extensive biotechnology industry leadership experience, including a successful track record in finance, corporate development and strategic leadership. As Alector's CFO, Dr. Grasso will lead all aspects of the company's financial operations and play a critical role in supporting corporate strategy. Dr. Grasso will report to Arnon Rosenthal, Ph.D., Chief Executive Officer of Alector. 

    2/7/22 8:30:00 AM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALEC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Alector Inc.

    SC 13G - Alector, Inc. (0001653087) (Subject)

    12/6/24 5:30:28 PM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Alector Inc.

    SC 13G/A - Alector, Inc. (0001653087) (Subject)

    11/12/24 7:21:57 PM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Alector Inc.

    SC 13G/A - Alector, Inc. (0001653087) (Subject)

    11/7/24 12:41:31 PM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care